Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% decreases the incidence of postoperative cystoid macular edema (CME), a sight-threatening complication of cataract surgery. The study results were presented at the joint annual meeting of the American Society of Cataract and Refractive Surgery and American Society